@article{MantelMuellerKleineetal.2021,
  author    = {Mantel, Frederick and M{\"u}ller, Elena and Kleine, Philip and Zimmermann, Marcus and Exner, Florian and Richter, Anne and Weick, Stefan and Str{\"o}hle, Serge and Polat, B{\"u}lent and H{\"o}cht, Stefan and Flentje, Michael},
  title     = {Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience},
  series = {Strahlentherapie und Onkologie},
  volume    = {197},
  journal   = {Strahlentherapie und Onkologie},
  number    = {5},
  issn      = {1439-099X},
  doi       = {10.1007/s00066-021-01756-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-264821},
  pages     = {405-415},
  year      = {2021},
  abstract  = {Purpose Integrating moderate hypofractionation to the macroscopic tumor with elective nodal irradiation while sparing the organs at risk (OAR) in chemoradiotherapy of locally advanced non-small-cell lung cancer. Methods From 2010-2018, treatment, patient and tumor characteristics of 138 patients from two radiation therapy centers were assessed. Chemoradiotherapy by intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost (SIB) to the primary tumor and macroscopic lymph node metastases was used. Results A total of 124 (90\%) patients received concurrent chemotherapy. 106 (76\%) patients had UICC (Union for International Cancer Control) stage ≥IIIB and 21 (15\%) patients had an oligometastatic disease (UICC stage IV). Median SIB and elective total dose was 61.6 and 50.4 Gy in 28 fractions, respectively. Furthermore, 64 patients (46\%) had an additional sequential boost to the primary tumor after the SIB-IMRT main series: median 6.6 Gy in median 3 fractions. The median cumulative mean lung dose was 15.6 Gy (range 6.2-29.5 Gy). Median follow-up and radiological follow-up for all patients was 18.0 months (range 0.6-86.9) and 16.0 months (range 0.2-86.9), respectively. Actuarial local control rates at 1, 2 and 3 years were 80.4, 68.4 and 57.8\%. Median overall survival and progression-free survival was 30.0 months (95\% confidence interval [CI] 23.5-36.4) and 12.1 months (95\% CI 8.2-16.0), respectively. Treatment-related toxicity was moderate. Radiation-induced pneumonitis grade 2 and grade 3 occurred in 13 (9.8\%) and 3 (2.3\%) patients. Conclusions Chemoradiotherapy using SIB-IMRT showed promising local tumor control rates and acceptable toxicity in patients with locally advanced and in part oligometastatic lung cancer. The SIB concept, resulting in a relatively low mean lung dose, was associated with low numbers of clinically relevant pneumonitis. The overall survival appears promising in the presence of a majority of patients with UICC stage ≥IIIB disease.},
  language  = {en}
}